Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT02947061

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Breast Cancer Recurrent Clinical Trial

Official title:
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer: a Phase 2, Prospective,Multicenter, Randomised Study

Clinical Trial Summary

To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With Advanced Breast Cancer first-line treatment

Clinical Trial Description

To compare progression free survival (PFS) of the S-1 combined with docetaxel followed by maintenance treatment with S-1 and capecitabine combined with docetaxel followed by maintenance therapy with capecitabine in patients with advanced breast cancer first-line treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02947061
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Binghe Xu, M.D.
Phone 010-87778826
Status Recruiting
Phase Phase 2
Start date April 2015
Completion date April 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. Phase 1
Recruiting NCT05592938 - Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) N/A
Completed NCT04330339 - Prolonged Nightly Fasting in Breast Cancer Survivors N/A
Active, not recruiting NCT02915445 - EpCAM CAR-T for Treatment of Advanced Solid Tumors Phase 1
Completed NCT02844335 - Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT05464082 - Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC Phase 2
Completed NCT05301010 - Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients Phase 3
Recruiting NCT05730608 - 18F-FDG PET/CT Imaging for Breast Cancer N/A
Completed NCT01552655 - Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT N/A
Not yet recruiting NCT05406661 - Registry of Local Recurrences After Breast-conserving Surgery
Recruiting NCT03820830 - Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Phase 3
Completed NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Phase 4